Objective
This project is concerned with the strategies for protection against influenza virus and has two main objectives:
- to use monoclonal antibodies of defined specificity to characterise with a view to optimising the protective immune response to vaccination;
- to understand how antibodies neutralise influenza virus infectivity.
The outstanding characteristic of influenza viruses is their ability to cause frequent epidemics of respiratory disease; each outbreak is caused by an antigenically distinct virus. Protection against influenza is mainly achieved by vaccination; the target in this approach is the hemagglutinin (HA), a viral membrane glycoprotein with which neutralising antibodies react. The main objective of this project, potentially of direct practical interest, is to gain a better understanding at the molecular level of the strategy for vaccination against influenza. This is made possible by recent advances in the functional and structural characterisation of influenza HA.
Specific goals include :
-Defining the 3-D structure of epitopes recognised by antibodies specific for the antigenic sites of HA, by determining the X-Ray structures of the complexes of these antibodies with HA.
-Characterising the mechanism of neutralisation by antibodies of structurally defined specificity.
-Comparing the potential for protection of antibodies specific for the different antigenic sites of influenza hemagglutinin.
-Comparing the HA-recognition specificity of neutralising antibodies elicited post-vaccination and in individuals recovering from infection.
Although the available vaccines induce good levels of antibodies, their overall protective efficacy against influenza disease is only about 70 per cent. The results of this project will inform decisions on vaccination regimens that are needed to improve the present situation.
The outstanding characteristic of influenza viruses is their ability to cause frequent epidemics of respiratory disease; anantigenically distinct virus causes each outbreak. Protection against influenza is mainly achieved by vaccination the target in this approach is the hemagglutinin (HA), a viral membrane glycoprotein with which neutralizing antibodies react. The main objective of this project, potentially of direct practical interest, is to gain a better understanding at the molecular level of the strategy for vaccination against influenza. This is made possible by recent advances in the functional and structural characterization of influenza HA.
Specific goals include:- Defining the 3-D structure of epitopes recognized by antibodies specific for the antigenic sites of HA, by determining the X-Ray structures of the complex of these antibodies with HA. -Characterising the mechanism of neutralization by antibodies of structurally defined specificity. -Comparing the potential for protection of antibodies specific for the different antigenic sites of influenza haemaglutinin. -Comparing the HA-recognition specificity of neutralizing antibodies elicited post-vaccination and in individuals recovering from infection. Although the available vaccines induce good levels of antibodies, their overall protective efficacy against influenza disease is only about 70 percent. The results of this project will inform decisions on vaccination regimens that are needed to improve the present situation.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses influenza
- medical and health sciences basic medicine immunology
- medical and health sciences health sciences infectious diseases RNA viruses coronaviruses
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
91198 GIF SUR YVETTE
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.